Fusobacterium nucleatum Potentiates Intestinal Tumorigenesis in Mice via a Toll-Like Receptor 4/p21-Activated Kinase 1 Cascade - PubMed (original) (raw)

. 2018 May;63(5):1210-1218.

doi: 10.1007/s10620-018-4999-2. Epub 2018 Mar 5.

Affiliations

• PMID: 29508166
• DOI: 10.1007/s10620-018-4999-2

Fusobacterium nucleatum Potentiates Intestinal Tumorigenesis in Mice via a Toll-Like Receptor 4/p21-Activated Kinase 1 Cascade

Yaxin Wu et al. Dig Dis Sci. 2018 May.

Abstract

Background: The underlying pathogenic mechanism of Fusobacterium nucleatum in the carcinogenesis of colorectal cancer has been poorly understood.

Methods: Using C57BL/6-ApcMin/+ mice, we investigated gut microbial structures with F. nucleatum, antibiotics, and Toll-like receptor 4 (TLR4) antagonist TAK-242 treatment. In addition, we measured intestinal tumor formation and the expression of TLR4, p21-activated kinase 1 (PAK1), phosphorylated-PAK1 (p-PAK1), phosphorylated-β-catenin S675 (p-β-catenin S675), and cyclin D1 in mice with different treatments.

Results: Fusobacterium nucleatum and antibiotics treatment altered gut microbial structures in mice. In addition, F. nucleatum invaded into the intestinal mucosa in large amounts but were less abundant in the feces of F. nucleatum-fed mice. The average number and size of intestinal tumors in F. nucleatum groups was significantly increased compared to control groups in ApcMin/+ mice (P < 0.05). The expression of TLR4, PAK1, p-PAK1, p-β-catenin S675, and cyclin D1 was significantly increased in F. nucleatum groups compared to the control groups (P < 0.05). Moreover, TAK-242 significantly decreased the average number and size of intestinal tumors compared to F. nucleatum groups (P < 0.05). The expression of p-PAK1, p-β-catenin S675, and cyclin D1 was also significantly decreased in the TAK-242-treated group compared to F. nucleatum groups (P < 0.05).

Conclusions: Fusobacterium nucleatum potentiates intestinal tumorigenesis in ApcMin/+ mice via a TLR4/p-PAK1/p-β-catenin S675 cascade. Fusobacterium nucleatum-induced intestinal tumorigenesis can be inhibited by TAK-242, implicating TLR4 as a potential target for the prevention and therapy of F. nucleatum-related colorectal cancer.

Keywords: Colorectal cancer; Fusobacterium nucleatum; Toll-like receptor 4; p21-activated kinase 1; β-Catenin signaling.

PubMed Disclaimer

Similar articles

• Invasive Fusobacterium nucleatum activates beta-catenin signaling in colorectal cancer via a TLR4/P-PAK1 cascade.
  Chen Y, Peng Y, Yu J, Chen T, Wu Y, Shi L, Li Q, Wu J, Fu X. Chen Y, et al. Oncotarget. 2017 May 9;8(19):31802-31814. doi: 10.18632/oncotarget.15992. Oncotarget. 2017. PMID: 28423670 Free PMC article.
• Fusobacterium nucleatum Increases Proliferation of Colorectal Cancer Cells and Tumor Development in Mice by Activating Toll-Like Receptor 4 Signaling to Nuclear Factor-κB, and Up-regulating Expression of MicroRNA-21.
  Yang Y, Weng W, Peng J, Hong L, Yang L, Toiyama Y, Gao R, Liu M, Yin M, Pan C, Li H, Guo B, Zhu Q, Wei Q, Moyer MP, Wang P, Cai S, Goel A, Qin H, Ma Y. Yang Y, et al. Gastroenterology. 2017 Mar;152(4):851-866.e24. doi: 10.1053/j.gastro.2016.11.018. Epub 2016 Nov 19. Gastroenterology. 2017. PMID: 27876571 Free PMC article.
• Berberine may rescue Fusobacterium nucleatum-induced colorectal tumorigenesis by modulating the tumor microenvironment.
  Yu YN, Yu TC, Zhao HJ, Sun TT, Chen HM, Chen HY, An HF, Weng YR, Yu J, Li M, Qin WX, Ma X, Shen N, Hong J, Fang JY. Yu YN, et al. Oncotarget. 2015 Oct 13;6(31):32013-26. doi: 10.18632/oncotarget.5166. Oncotarget. 2015. PMID: 26397137 Free PMC article.
• Association of Fusobacterium nucleatum with immunity and molecular alterations in colorectal cancer.
  Nosho K, Sukawa Y, Adachi Y, Ito M, Mitsuhashi K, Kurihara H, Kanno S, Yamamoto I, Ishigami K, Igarashi H, Maruyama R, Imai K, Yamamoto H, Shinomura Y. Nosho K, et al. World J Gastroenterol. 2016 Jan 14;22(2):557-66. doi: 10.3748/wjg.v22.i2.557. World J Gastroenterol. 2016. PMID: 26811607 Free PMC article. Review.
• Fusobacterium nucleatum: an emerging bug in colorectal tumorigenesis.
  Bashir A, Miskeen AY, Bhat A, Fazili KM, Ganai BA. Bashir A, et al. Eur J Cancer Prev. 2015 Sep;24(5):373-85. doi: 10.1097/CEJ.0000000000000116. Eur J Cancer Prev. 2015. PMID: 25569450 Review.

Cited by

• Human microbiomes in cancer development and therapy.
  Xia C, Su J, Liu C, Mai Z, Yin S, Yang C, Fu L. Xia C, et al. MedComm (2020). 2023 Feb 26;4(2):e221. doi: 10.1002/mco2.221. eCollection 2023 Apr. MedComm (2020). 2023. PMID: 36860568 Free PMC article. Review.
• The role of microbiota in the development of colorectal cancer.
  Dai Z, Zhang J, Wu Q, Chen J, Liu J, Wang L, Chen C, Xu J, Zhang H, Shi C, Li Z, Fang H, Lin C, Tang D, Wang D. Dai Z, et al. Int J Cancer. 2019 Oct 15;145(8):2032-2041. doi: 10.1002/ijc.32017. Epub 2019 Jan 15. Int J Cancer. 2019. PMID: 30474116 Free PMC article. Review.
• A Review of the Role of Oral Microbiome in the Development, Detection, and Management of Head and Neck Squamous Cell Cancers.
  Burcher KM, Burcher JT, Inscore L, Bloomer CH, Furdui CM, Porosnicu M. Burcher KM, et al. Cancers (Basel). 2022 Aug 25;14(17):4116. doi: 10.3390/cancers14174116. Cancers (Basel). 2022. PMID: 36077651 Free PMC article. Review.
• Fusobacterium nucleatum and colorectal cancer: From phenomenon to mechanism.
  Ou S, Wang H, Tao Y, Luo K, Ye J, Ran S, Guan Z, Wang Y, Hu H, Huang R. Ou S, et al. Front Cell Infect Microbiol. 2022 Nov 29;12:1020583. doi: 10.3389/fcimb.2022.1020583. eCollection 2022. Front Cell Infect Microbiol. 2022. PMID: 36523635 Free PMC article. Review.
• Precision strategies for cancer treatment by modifying the tumor-related bacteria.
  Lu H, Wang Q, Liu W, Wen Z, Li Y. Lu H, et al. Appl Microbiol Biotechnol. 2021 Aug;105(16-17):6183-6197. doi: 10.1007/s00253-021-11491-9. Epub 2021 Aug 17. Appl Microbiol Biotechnol. 2021. PMID: 34402938 Review.

References

1. 1. Inflamm Bowel Dis. 2011 Jul;17(7):1464-73 - PubMed
2. 1. Nature. 2014 May 15;509(7500):357-60 - PubMed
3. 1. Biochim Biophys Acta. 2003 Jun 5;1653(1):1-24 - PubMed
4. 1. PLoS One. 2011;6(5):e20447 - PubMed
5. 1. Cancer Prev Res (Phila). 2015 Nov;8(11):1093-101 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Springer

• Other Literature Sources

  • scite Smart Citations

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal